Abstract
<dm:abstracts xmlns:dm="http://www.elsevier.com/xml/dm/dtd"><ce:abstract xmlns:ce="http://www.elsevier.com/xml/common/dtd" id="abs0010" view="all" class="author"><ce:section-title id="sect0005">Resumo</ce:section-title><ce:abstract-sec id="abst0005" view="all"><ce:simple-para id="spar0005" view="all">A anemia muitas vezes se desenvolve em pacientes com artrite reumatoide (AR). No presente estudo, examinou‐se a associação entre a eficácia terapêutica do agente biológico tocilizumab (TCZ) e potenciais preditores de eficácia terapêutica. Focou‐se na melhoria da anemia da inflamação crônica por meio do mecanismo de inibição direta dos sinais mediados pelo receptor da interleucina (IL)‐6 pelo TCZ. A hepcidina‐25 sérica, que é expressa de maneira dependente da IL‐6 e é uma das principais causas da anemia da inflamação crônica, foi medida em 10 pacientes com AR, antes e após a administração de TCZ. Compararam‐se os achados com a IL‐6 e com alterações nos dados clínicos para avaliar se a hepcidina‐25 poderia atuar como um preditor da eficácia do TCZ. Observaram‐se um nível sérico elevado de hepcidina‐25 na maior parte dos pacientes com AR e um decréscimo após a administração de TCZ; a maior parte dos pacientes teve respostas favoráveis ao tratamento. Um subgrupo de pacientes teve níveis séricos normais ou baixos de hepcidina‐25 antes da administração, níveis aumentados após a administração e má resposta ao tratamento com TCZ. Esses resultados sugerem que a hepcidina‐25 pode ser um preditor da resposta clínica ao TCZ.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:abstract xmlns:ce="http://www.elsevier.com/xml/common/dtd" id="abs0005" xml:lang="en" view="all" class="author"><ce:section-title id="sect0010">Abstract</ce:section-title><ce:abstract-sec id="abst0010" view="all"><ce:simple-para id="spar0010" view="all">Anemia often develops in rheumatoid arthritis (RA) patients. In the present study, we examined the association between the therapeutic effectiveness of the biologic agent tocilizumab (TCZ) and potential predictors of therapeutic effectiveness. We focused on the amelioration of anemia of chronic inflammation through the mechanism of direct inhibition of Interleukin (IL)‐6 receptor‐mediated signals by TCZ. Serum hepcidin‐25, which is expressed in an IL‐6 dependent manner and is a major cause of anemia of chronic inflammation, was measured in 10 RA patients, before and after administration of TCZ. We compared the findings with IL‐6 and changes in clinical data, to assess whether hepcidin‐25 could act as a predictor of the effectiveness of TCZ. A high level of serum hepcidin‐25 was observed in most RA patients, and a decrease was noted after administration of TCZ; most patients had favorable treatment responses. A subgroup of patients had normal or low serum hepcidin‐25 levels before administration, increased levels after administration, and poor treatment responses to TCZ. These results suggest that hepcidin‐25 may be a predictor of clinical response to TCZ.</ce:simple-para></ce:abstract-sec></ce:abstract></dm:abstracts>
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
